270 reports of this reaction
2.6% of all BUROSUMAB reports
#7 most reported adverse reaction
RESTLESS LEGS SYNDROME is the #7 most commonly reported adverse reaction for BUROSUMAB, manufactured by Kyowa Kirin, Inc.. There are 270 FDA adverse event reports linking BUROSUMAB to RESTLESS LEGS SYNDROME. This represents approximately 2.6% of all 10,519 adverse event reports for this drug.
Patients taking BUROSUMAB who experience restless legs syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RESTLESS LEGS SYNDROME is a less commonly reported adverse event for BUROSUMAB, but still significant enough to appear in the safety profile.
In addition to restless legs syndrome, the following adverse reactions have been reported for BUROSUMAB:
RESTLESS LEGS SYNDROME has been reported as an adverse event in 270 FDA reports for BUROSUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
RESTLESS LEGS SYNDROME accounts for approximately 2.6% of all adverse event reports for BUROSUMAB, making it a notable side effect.
If you experience restless legs syndrome while taking BUROSUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.